Oncomed Pharmaceuticals Inc., of Redwood City, Calif., said it completed its underwritten public offering of 6.32 million shares of its common stock at $10 each, which includes the exercise in full of the underwriters' right to purchase up to an additional 825,000 shares of common stock.